Here are the top five most-viewed articles about healthcare and drug costs that were posted on the Managed Healthcare Executive website in 2023.

The Future of Savings in Humira Biosimilars Drug Costs Are Low

As a Humira biosimilars are set to enter the market this year, it seems to be unlikely that they will drive down drug costs in the future.

Read more

No Prescription Needed. But Will Insurers Cover OTC Hearing Aids?

Commercial plans haven’t traditionally covered hearing aids.

Read more

Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023

Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne muscular dystrophy priced at between $2 million and $3 million.

Read more

Inpefa, a New Heart Failure Drug, Surpasses Cost-Effectiveness Threshold

Inpefa (sotagliflozin) added 0.39 quality of life years at an incremental lifetime cost of $29,449 for an incremental cost-effectiveness ratio of $75,510 per quality-of-life year gained, according to the study that was sponsored by the drug's maker, Lexicon Pharmaceuticals.

Read more

Off-label Use of Avastin in Diabetic Macular Edema More Cost-Effective Than Eylea

Starting with Avastin to treat patients with diabetic macular edema — and switching to Eylea if patients don’t have a response — could result in savings of more than $125 million.

Read more